When you are preparing for chemotherapy, nutrition can suddenly become confusing. You may be told to eat enough to maintain your strength. Then you hear that fasting before chemotherapy may help the body tolerate treatment. It is understandable to wonder how both ideas can be true.
Research into fasting and chemotherapy is giving us some interesting answers. Several clinical studies suggest short-term fasting may reduce certain treatment side effects. It may also affect how tumors respond to chemotherapy. However, fasting is not appropriate for every patient and should always be medically supervised.
Clinical trials have used several different fasting schedules. One common approach begins 24 to 36 hours before chemotherapy. Fasting may then continue until about 24 hours after the infusion.
This creates a total fasting period of roughly 48 to 72 hours. Some studies have investigated periods as long as 96 hours. However, these longer periods are less common.
Water is generally permitted during the fasting protocols studied. Adequate hydration remains important during cancer treatment.
Depending on the research protocol, patients may also be allowed:
A fasting-mimicking diet, or FMD, is another approach researchers are studying. It is not the same as a water-only fast.
The FMD provides a very small amount of food each day. The supporting research describes protocols around 600 calories daily. Foods may include plant-based soups, crackers, broths, and herbal teas.
The biology behind this approach is fascinating. One important concept is called differential stress resistance.
When food becomes temporarily unavailable, healthy cells receive a clear metabolic message. This is not a good time for rapid growth.
Instead, normal cells may shift resources toward maintenance and protection. Think of it as temporarily moving from growth mode into conservation mode.
During fasting, several metabolic changes can occur, including:
Cancer cells behave differently because their growth signals are often abnormal. They may continue pushing toward growth despite reduced nutrient availability.
Researchers propose that cancer cells cannot enter the same protective state as healthy cells. Therefore, chemotherapy may continue damaging cancer cells while normal cells become more resistant to stress.
One of the most important studies was the DIRECT trial. This multicenter randomized phase 2 trial included 131 patients with early-stage breast cancer.
Patients received chemotherapy before surgery. Researchers randomly assigned them to follow either their normal diet or a fasting-mimicking diet. The FMD was used for three days before chemotherapy and on the treatment day.
Researchers reported several noteworthy findings. Patients following the FMD were more likely to experience complete or partial tumor shrinkage on imaging.
They were also nearly four times more likely to achieve 90 to 100 percent tumor cell destruction at surgery. Researchers also found less chemotherapy-related DNA damage in immune cells.
A 2024 randomized controlled trial included 44 breast cancer patients receiving chemotherapy before surgery. Patients were studied across eight treatment cycles.
The fasting-mimicking group showed improvements in several areas. These included treatment side effects, blood markers, and tumor response.
Researchers reported:
One of the newest studies was presented at the 2026 American Society of Clinical Oncology Annual Meeting. It involved women with advanced high-grade serous ovarian cancer.
The randomized pilot trial included 36 women. Patients either followed their usual diet or completed short-term fasting around chemotherapy.
Women in the fasting group stopped eating 36 hours before chemotherapy. They continued fasting for another 24 hours afterward.
Water remained permitted throughout the fasting period. Patients followed the protocol around three chemotherapy cycles before surgery.
The study's main objective involved insulin. Insulin levels decreased in the fasting group but increased in the regular-diet group.
The tumor findings were especially interesting. Nearly three in five fasting patients had a complete or near-complete response before surgery.
The regular-diet group had a substantially lower response rate. Researchers also reported a notable difference in cancer progression.
Patients in the fasting group went about three years before progression or recurrence. The comparison group reached that point at approximately two years.
Researchers also found early evidence of favorable changes in immune cell activity. Importantly, the fasting protocol was well tolerated in this small trial.
For many patients, this may be the most immediate question. Chemotherapy can cause side effects that significantly affect daily life.
A 2024 systematic review examined seven randomized controlled trials. It found meaningful reductions in several symptoms among fasting patients.
Reported improvements included:
Chemotherapy targets rapidly dividing cancer cells. Unfortunately, it can also affect healthy cells.
Fasting may change the environment surrounding those healthy cells. Lower insulin, glucose, and growth signaling may encourage cells to focus on maintenance rather than growth.
This could potentially reduce some unintended chemotherapy damage. Researchers are also examining fasting's effects on inflammation, metabolism, and immune function.
Some patients in trials have reported another benefit. Participating in a structured nutrition strategy gave them a greater sense of involvement in their treatment.
The research cited in the supporting article does not recommend fasting for patients who are underweight or malnourished. Uncontrolled diabetes is another important concern.
Fasting may be inappropriate for someone experiencing:
Some people with cancer experience cachexia. This involves ongoing weight and muscle loss that cannot be corrected simply by eating more.
For these patients, preserving nutritional status can become a major treatment priority. Adding a fasting protocol may be inappropriate.
There is no benefit in forcing a promising nutritional strategy onto the wrong patient. Good integrative medicine always starts with the individual.
If you are interested in fasting, speak with your oncology team before changing your diet. Ideally, your oncologist and integrative healthcare professional should communicate about the plan.
The fasting research itself reflects this supervised approach. Patients in clinical protocols receive guidance before starting.
A healthcare professional may need to consider:
Fasting before chemotherapy challenges the old assumption that nutrition only matters between treatments. Research suggests metabolism may influence how healthy and cancerous cells respond during treatment itself. That possibility deserves serious scientific attention.
At the same time, the decision must remain individualized. Your cancer type, treatment, weight, metabolic health, and nutritional status all matter. The better question is not simply, "Should I fast?" It is whether a supervised fasting strategy makes sense for you.
If you are undergoing cancer treatment, you should not have to sort through conflicting health information alone. At the Stengler Center, we take an individualized and evidence-based approach to integrative cancer support.
We can help you evaluate nutrition and other supportive strategies alongside your oncology care. Contact us to discuss a personalized approach designed around your health and treatment needs.
Stengler Center for Integrative Medicine
324 Encinitas Blvd
Encinitas, CA 92024
Phone: 760-274-2377
Toll-Free: 855-DOC-MARK
Email: clinic@markstengler.com
Office Hours:
Monday through Thursday: 8:30 a.m. to 4:00 p.m.
Friday: 8:30 a.m. to 2:00 p.m.
